FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053447148> ?p ?o ?g. }

• W2053447148 endingPage "616" @default.
• W2053447148 startingPage "612" @default.
• W2053447148 abstract "IntroductionRecent clinical trials have shown significant survival benefits from postoperative adjuvant therapy for respectable nonsmall cell lung cancer (NSCLC). However, evaluation of adjuvant chemotherapy with carboplatin combination is still uncertain. The purpose of the study was to test the feasibility of adjuvant chemotherapy with carboplatin and separate weekly paclitaxel after complete resection of pStage IB, II, IIIA NSCLC in a multicenter study.MethodsThe study was conducted from 2001 to 2006 in the outpatient setting. A total of 61 patients were enrolled. Patients received adjuvant chemotherapy with 4 cycles of carboplatin (AUC 5) on day 1 and paclitaxel (70 mg/m2) on day 1, 8, and 15 every 4 weeks. Primary endpoints were toxicity and chemotherapy compliance. Secondary endpoints were disease-free survival and overall survival.ResultsMore than 65% of eligible patients had pStage IIIA. The median number of chemotherapy cycles was 4 (range 1–4). Grade 3 or 4 toxicities of neutropenia were 34% (grade 4: 2%). Other hematologic adverse effects were extremely less frequent. Regarding the nonhematologic adverse effect, hair loss was frequent; however, peripheral neuralgia was less frequent. Treatment-related death was not registered. During median follow-up of 21 months, 24 patients developed recurrent disease. Estimated disease-free survival and overall survival at 2 years was 51.2% and 84.6%, respectively.ConclusionsPostoperative carboplatin and weekly paclitaxel showed favorable feasibility and acceptable toxicity in comparison with the cisplatin-containing regimen. Consequently, it is desirable that this regimen would be validated in a phase III clinical trial for NSCLC after curative resection. Recent clinical trials have shown significant survival benefits from postoperative adjuvant therapy for respectable nonsmall cell lung cancer (NSCLC). However, evaluation of adjuvant chemotherapy with carboplatin combination is still uncertain. The purpose of the study was to test the feasibility of adjuvant chemotherapy with carboplatin and separate weekly paclitaxel after complete resection of pStage IB, II, IIIA NSCLC in a multicenter study. The study was conducted from 2001 to 2006 in the outpatient setting. A total of 61 patients were enrolled. Patients received adjuvant chemotherapy with 4 cycles of carboplatin (AUC 5) on day 1 and paclitaxel (70 mg/m2) on day 1, 8, and 15 every 4 weeks. Primary endpoints were toxicity and chemotherapy compliance. Secondary endpoints were disease-free survival and overall survival. More than 65% of eligible patients had pStage IIIA. The median number of chemotherapy cycles was 4 (range 1–4). Grade 3 or 4 toxicities of neutropenia were 34% (grade 4: 2%). Other hematologic adverse effects were extremely less frequent. Regarding the nonhematologic adverse effect, hair loss was frequent; however, peripheral neuralgia was less frequent. Treatment-related death was not registered. During median follow-up of 21 months, 24 patients developed recurrent disease. Estimated disease-free survival and overall survival at 2 years was 51.2% and 84.6%, respectively. Postoperative carboplatin and weekly paclitaxel showed favorable feasibility and acceptable toxicity in comparison with the cisplatin-containing regimen. Consequently, it is desirable that this regimen would be validated in a phase III clinical trial for NSCLC after curative resection." @default.
• W2053447148 created "2016-06-24" @default.
• W2053447148 creator A5005496257 @default.
• W2053447148 creator A5009932798 @default.
• W2053447148 creator A5013107055 @default.
• W2053447148 creator A5036142979 @default.
• W2053447148 creator A5052311523 @default.
• W2053447148 creator A5060557304 @default.
• W2053447148 creator A5062879016 @default.
• W2053447148 creator A5064178270 @default.
• W2053447148 creator A5066959571 @default.
• W2053447148 creator A5069392282 @default.
• W2053447148 creator A5079332584 @default.
• W2053447148 creator A5079670572 @default.
• W2053447148 creator A5086604528 @default.
• W2053447148 date "2008-06-01" @default.
• W2053447148 modified "2023-10-18" @default.
• W2053447148 title "A Feasibility Study of Postoperative Adjuvant Therapy of Carboplatin and Weekly Paclitaxel for Completely Resected Non-small Cell Lung Cancer" @default.
• W2053447148 cites W1775557217 @default.
• W2053447148 cites W1941410407 @default.
• W2053447148 cites W1989652669 @default.
• W2053447148 cites W1993312546 @default.
• W2053447148 cites W1994645410 @default.
• W2053447148 cites W1996654617 @default.
• W2053447148 cites W2034009362 @default.
• W2053447148 cites W2047302001 @default.
• W2053447148 cites W2075549113 @default.
• W2053447148 cites W2098126133 @default.
• W2053447148 cites W2113587402 @default.
• W2053447148 cites W2116996913 @default.
• W2053447148 cites W2127342594 @default.
• W2053447148 cites W2138289140 @default.
• W2053447148 cites W2147869809 @default.
• W2053447148 cites W2158234609 @default.
• W2053447148 cites W2210791796 @default.
• W2053447148 cites W2426686874 @default.
• W2053447148 cites W2498989817 @default.
• W2053447148 doi "https://doi.org/10.1097/jto.0b013e318174e05e" @default.
• W2053447148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18520800" @default.
• W2053447148 hasPublicationYear "2008" @default.
• W2053447148 type Work @default.
• W2053447148 sameAs 2053447148 @default.
• W2053447148 citedByCount "8" @default.
• W2053447148 countsByYear W20534471482015 @default.
• W2053447148 countsByYear W20534471482017 @default.
• W2053447148 countsByYear W20534471482018 @default.
• W2053447148 countsByYear W20534471482019 @default.
• W2053447148 crossrefType "journal-article" @default.
• W2053447148 hasAuthorship W2053447148A5005496257 @default.
• W2053447148 hasAuthorship W2053447148A5009932798 @default.
• W2053447148 hasAuthorship W2053447148A5013107055 @default.
• W2053447148 hasAuthorship W2053447148A5036142979 @default.
• W2053447148 hasAuthorship W2053447148A5052311523 @default.
• W2053447148 hasAuthorship W2053447148A5060557304 @default.
• W2053447148 hasAuthorship W2053447148A5062879016 @default.
• W2053447148 hasAuthorship W2053447148A5064178270 @default.
• W2053447148 hasAuthorship W2053447148A5066959571 @default.
• W2053447148 hasAuthorship W2053447148A5069392282 @default.
• W2053447148 hasAuthorship W2053447148A5079332584 @default.
• W2053447148 hasAuthorship W2053447148A5079670572 @default.
• W2053447148 hasAuthorship W2053447148A5086604528 @default.
• W2053447148 hasBestOaLocation W20534471481 @default.
• W2053447148 hasConcept C126322002 @default.
• W2053447148 hasConcept C141071460 @default.
• W2053447148 hasConcept C143998085 @default.
• W2053447148 hasConcept C197934379 @default.
• W2053447148 hasConcept C203092338 @default.
• W2053447148 hasConcept C2776256026 @default.
• W2053447148 hasConcept C2776694085 @default.
• W2053447148 hasConcept C2777063308 @default.
• W2053447148 hasConcept C2777292972 @default.
• W2053447148 hasConcept C2777982462 @default.
• W2053447148 hasConcept C2778239845 @default.
• W2053447148 hasConcept C2781413609 @default.
• W2053447148 hasConcept C2781451048 @default.
• W2053447148 hasConcept C535046627 @default.
• W2053447148 hasConcept C71924100 @default.
• W2053447148 hasConceptScore W2053447148C126322002 @default.
• W2053447148 hasConceptScore W2053447148C141071460 @default.
• W2053447148 hasConceptScore W2053447148C143998085 @default.
• W2053447148 hasConceptScore W2053447148C197934379 @default.
• W2053447148 hasConceptScore W2053447148C203092338 @default.
• W2053447148 hasConceptScore W2053447148C2776256026 @default.
• W2053447148 hasConceptScore W2053447148C2776694085 @default.
• W2053447148 hasConceptScore W2053447148C2777063308 @default.
• W2053447148 hasConceptScore W2053447148C2777292972 @default.
• W2053447148 hasConceptScore W2053447148C2777982462 @default.
• W2053447148 hasConceptScore W2053447148C2778239845 @default.
• W2053447148 hasConceptScore W2053447148C2781413609 @default.
• W2053447148 hasConceptScore W2053447148C2781451048 @default.
• W2053447148 hasConceptScore W2053447148C535046627 @default.
• W2053447148 hasConceptScore W2053447148C71924100 @default.
• W2053447148 hasIssue "6" @default.
• W2053447148 hasLocation W20534471481 @default.
• W2053447148 hasLocation W20534471482 @default.
• W2053447148 hasOpenAccess W2053447148 @default.
• W2053447148 hasPrimaryLocation W20534471481 @default.
• W2053447148 hasRelatedWork W182989684 @default.

• next